<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34684016</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">1999-4923</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutics</Title>
          <ISOAbbreviation>Pharmaceutics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Future Perspectives of Oral Delivery of Next Generation Therapies for Treatment of Skin Diseases.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1722</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics13101722</ELocationID>
        <Abstract>
          <AbstractText>Gene therapies have conspicuously bloomed in recent years as evidenced by the increasing number of cell-, gene-, and oligo-based approved therapies. These therapies hold great promise for dermatological disorders with high unmet need, for example, epidermolysis bullosa or pachyonychia congenita. Furthermore, the recent clinical success of clustered regularly interspaced short palindromic repeats (CRISPR) for genome editing in humans will undoubtedly contribute to defining a new wave of therapies. Like biologics, naked nucleic acids are denatured inside the gastrointestinal tract and need to be administered via injections. For a treatment to be effective, a sufficient amount of a given regimen needs to reach systemic circulation. Multiple companies are racing to develop novel oral drug delivery approaches to circumvent the proteolytic and acidic milieu of the gastrointestinal tract. In this review, we provide an overview of the evolution of the gene therapy landscape, with a deep focus on gene and oligonucleotide therapies in clinical trials aimed at treating skin diseases. We then examine the progress made in drug delivery, with particular attention on the peptide field and drug-device combinations that deliver macromolecules into the gastrointestinal tract. Such novel devices could potentially be applied to administer other therapeutics including genes and CRISPR-based systems.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Søgaard</LastName>
            <ForeName>Pia Pernille</ForeName>
            <Initials>PP</Initials>
            <AffiliationInfo>
              <Affiliation>Regenerative Medicine Department, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lind</LastName>
            <ForeName>Marianne</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-0188-5408</Identifier>
            <AffiliationInfo>
              <Affiliation>Explorative Formulation and Technologies, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Christiansen</LastName>
            <ForeName>Chatpakorn Rassemeena</ForeName>
            <Initials>CR</Initials>
            <AffiliationInfo>
              <Affiliation>Regenerative Medicine Department, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Petersson</LastName>
            <ForeName>Karsten</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Explorative Formulation and Technologies, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clauss</LastName>
            <ForeName>Adam</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Regenerative Medicine Department, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Caffarel-Salvador</LastName>
            <ForeName>Ester</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-2844-7598</Identifier>
            <AffiliationInfo>
              <Affiliation>Regenerative Medicine Department, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>LEO Science &amp; Tech Hub, One Broadway, Cambridge, MA 02142, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharmaceutics</MedlineTA>
        <NlmUniqueID>101534003</NlmUniqueID>
        <ISSNLinking>1999-4923</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CRISPR</Keyword>
        <Keyword MajorTopicYN="N">clinical trials</Keyword>
        <Keyword MajorTopicYN="N">drug-device combinations</Keyword>
        <Keyword MajorTopicYN="N">epidermolysis bullosa</Keyword>
        <Keyword MajorTopicYN="N">gene therapy</Keyword>
        <Keyword MajorTopicYN="N">oligonucleotides</Keyword>
        <Keyword MajorTopicYN="N">oral biologics</Keyword>
        <Keyword MajorTopicYN="N">oral devices</Keyword>
        <Keyword MajorTopicYN="N">regenerative medicine</Keyword>
        <Keyword MajorTopicYN="N">skin diseases</Keyword>
      </KeywordList>
      <CoiStatement>P.P.S., M.L., C.R.C., K.P., A.C. and E.C.-S. are LEO Pharma employees. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>23</Day>
          <Hour>1</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34684016</ArticleId>
        <ArticleId IdType="pmc">PMC8537019</ArticleId>
        <ArticleId IdType="doi">10.3390/pharmaceutics13101722</ArticleId>
        <ArticleId IdType="pii">pharmaceutics13101722</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fakhr E., Zare F., Teimoori-Toolabi L. Precise and efficient siRNA design: A key point in competent gene silencing. Cancer Gene Ther. 2016;23:73–82. doi: 10.1038/cgt.2016.4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cgt.2016.4</ArticleId>
            <ArticleId IdType="pubmed">26987292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts T.C., Langer R., Wood M.J.A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 2020;19:673–694. doi: 10.1038/s41573-020-0075-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41573-020-0075-7</ArticleId>
            <ArticleId IdType="pmc">PMC7419031</ArticleId>
            <ArticleId IdType="pubmed">32782413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu B., Zhong L., Weng Y., Peng L., Huang Y., Zhao Y., Liang X.J. Therapeutic siRNA: State of the art. Signal Transduct. Target. Ther. 2020;5:101. doi: 10.1038/s41392-020-0207-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-0207-x</ArticleId>
            <ArticleId IdType="pmc">PMC7305320</ArticleId>
            <ArticleId IdType="pubmed">32561705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulkarni J.A., Witzigmann D., Thomson S.B., Chen S., Leavitt B.R., Cullis P.R., van der Meel R. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 2021;16:630–643. doi: 10.1038/s41565-021-00898-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41565-021-00898-0</ArticleId>
            <ArticleId IdType="pubmed">34059811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc. J. 2016;4:35–50. doi: 10.14304/SURYA.JPR.V4N7.5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14304/SURYA.JPR.V4N7.5</ArticleId>
            <ArticleId IdType="pmc">PMC4995773</ArticleId>
            <ArticleId IdType="pubmed">27570789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Svoboda P. Key Mechanistic Principles and Considerations Concerning RNA Interference. Front. Plant Sci. 2020;11:1237. doi: 10.3389/fpls.2020.01237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fpls.2020.01237</ArticleId>
            <ArticleId IdType="pmc">PMC7438612</ArticleId>
            <ArticleId IdType="pubmed">32903622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J. RNA-Cleaving DNAzymes: Old Catalysts with New Tricks for Intracellular and In Vivo Applications. Catalysts. 2018;8:550.  doi: 10.3390/catal8110550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/catal8110550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Nguyen K., Spitale R.C., Chaput J.C. A biologically stable DNAzyme that efficiently silences gene expression in cells. Nat. Chem. 2021;13:319–326. doi: 10.1038/s41557-021-00645-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41557-021-00645-x</ArticleId>
            <ArticleId IdType="pubmed">33767363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibrahim R., Purath U., Turowska A., Homburg U., Runkel F., Schmidts T., Dobler D., Renz H., Garn H., Mueller A. Effects of interference with GATA-3 expression by target-specific DNAzyme treatment on disease progression in a subacute oxazolone-induced mouse model of atopic dermatitis. Clin. Transl. Allergy. 2015;5:O21. doi: 10.1186/2045-7022-5-S1-O21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2045-7022-5-S1-O21</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allemailem K.S., Almatroudi A., Alsahli M.A., Basfar G.T., Alrumaihi F., Rahmani A.H., Khan A.A. Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents. 3 Biotech. 2020;10:551. doi: 10.1007/s13205-020-02546-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13205-020-02546-1</ArticleId>
            <ArticleId IdType="pmc">PMC7686427</ArticleId>
            <ArticleId IdType="pubmed">33269185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giudice V., Mensitieri F., Izzo V., Filippelli A., Selleri C. Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases. Int. J. Mol. Sci. 2020;21:3252.  doi: 10.3390/ijms21093252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21093252</ArticleId>
            <ArticleId IdType="pmc">PMC7246934</ArticleId>
            <ArticleId IdType="pubmed">32375354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanton R., Sciabola S., Salatto C., Weng Y., Moshinsky D., Little J., Walters E., Kreeger J., DiMattia D., Chen T., et al.  Chemical modification study of antisense gapmers. Nucleic Acid Ther. 2012;22:344–359. doi: 10.1089/nat.2012.0366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/nat.2012.0366</ArticleId>
            <ArticleId IdType="pubmed">22852836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Layzer J.M., McCaffrey A.P., Tanner A.K., Huang Z., Kay M.A., Sullenger B.A. In vivo activity of nuclease-resistant siRNAs. RNA. 2004;10:766–771. doi: 10.1261/rna.5239604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1261/rna.5239604</ArticleId>
            <ArticleId IdType="pmc">PMC1370566</ArticleId>
            <ArticleId IdType="pubmed">15100431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan W.B., Seth P.P. The Medicinal Chemistry of Therapeutic Oligonucleotides. J. Med. Chem. 2016;59:9645–9667. doi: 10.1021/acs.jmedchem.6b00551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.6b00551</ArticleId>
            <ArticleId IdType="pubmed">27434100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chernikov I.V., Vlassov V.V., Chernolovskaya E.L. Current Development of siRNA Bioconjugates: From Research to the Clinic. Front. Pharmacol. 2019;10:444. doi: 10.3389/fphar.2019.00444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2019.00444</ArticleId>
            <ArticleId IdType="pmc">PMC6498891</ArticleId>
            <ArticleId IdType="pubmed">31105570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sajid M.I., Moazzam M., Kato S., Yeseom Cho K., Tiwari R.K. Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside. Pharmaceuticals. 2020;13:294.  doi: 10.3390/ph13100294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph13100294</ArticleId>
            <ArticleId IdType="pmc">PMC7600125</ArticleId>
            <ArticleId IdType="pubmed">33036435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Springer A.D., Dowdy S.F. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Nucleic Acid Ther. 2018;28:109–118. doi: 10.1089/nat.2018.0736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/nat.2018.0736</ArticleId>
            <ArticleId IdType="pmc">PMC5994659</ArticleId>
            <ArticleId IdType="pubmed">29792572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal S., Simon A.R., Goel V., Habtemariam B.A., Clausen V.A., Kim J.B., Robbie G.J. Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients with Acute Hepatic Porphyria. Clin. Pharmacol. Ther. 2020;108:63–72. doi: 10.1002/cpt.1802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cpt.1802</ArticleId>
            <ArticleId IdType="pubmed">31994716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doudna J.A. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229–236. doi: 10.1038/s41586-020-1978-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-1978-5</ArticleId>
            <ArticleId IdType="pubmed">32051598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komor A.C., Kim Y.B., Packer M.S., Zuris J.A., Liu D.R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420–424. doi: 10.1038/nature17946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature17946</ArticleId>
            <ArticleId IdType="pmc">PMC4873371</ArticleId>
            <ArticleId IdType="pubmed">27096365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kantor A., McClements M.E., MacLaren R.E. CRISPR-Cas9 DNA Base-Editing and Prime-Editing. Int. J. Mol. Sci. 2020;21:6240.  doi: 10.3390/ijms21176240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21176240</ArticleId>
            <ArticleId IdType="pmc">PMC7503568</ArticleId>
            <ArticleId IdType="pubmed">32872311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knott G.J., Doudna J.A. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361:866–869. doi: 10.1126/science.aat5011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aat5011</ArticleId>
            <ArticleId IdType="pmc">PMC6455913</ArticleId>
            <ArticleId IdType="pubmed">30166482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porto E.M., Komor A.C., Slaymaker I.M., Yeo G.W. Base editing: Advances and therapeutic opportunities. Nat. Rev. Drug Discov. 2020;19:839–859. doi: 10.1038/s41573-020-0084-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41573-020-0084-6</ArticleId>
            <ArticleId IdType="pmc">PMC7721651</ArticleId>
            <ArticleId IdType="pubmed">33077937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komor A.C., Badran A.H., Liu D.R. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell. 2017;168:20–36. doi: 10.1016/j.cell.2016.10.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.10.044</ArticleId>
            <ArticleId IdType="pmc">PMC5235943</ArticleId>
            <ArticleId IdType="pubmed">27866654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rees H.A., Minella A.C., Burnett C.A., Komor A.C., Gaudelli N.M. CRISPR-derived genome editing therapies: Progress from bench to bedside. Mol Ther. 2021 doi: 10.1016/j.ymthe.2021.09.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2021.09.027</ArticleId>
            <ArticleId IdType="pmc">PMC8572140</ArticleId>
            <ArticleId IdType="pubmed">34619370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anzalone A.V., Randolph P.B., Davis J.R., Sousa A.A., Koblan L.W., Levy J.M., Chen P.J., Wilson C., Newby G.A., Raguram A., et al.  Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–157. doi: 10.1038/s41586-019-1711-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1711-4</ArticleId>
            <ArticleId IdType="pmc">PMC6907074</ArticleId>
            <ArticleId IdType="pubmed">31634902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lino C.A., Harper J.C., Carney J.P., Timlin J.A. Delivering CRISPR: A review of the challenges and approaches. Drug Deliv. 2018;25:1234–1257. doi: 10.1080/10717544.2018.1474964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10717544.2018.1474964</ArticleId>
            <ArticleId IdType="pmc">PMC6058482</ArticleId>
            <ArticleId IdType="pubmed">29801422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta A., Merkel O.M. Immunogenicity of Cas9 Protein. J. Pharm. Sci. 2020;109:62–67. doi: 10.1016/j.xphs.2019.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xphs.2019.10.003</ArticleId>
            <ArticleId IdType="pmc">PMC7115921</ArticleId>
            <ArticleId IdType="pubmed">31589876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillmore J.D., Gane E., Taubel J., Kao J., Fontana M., Maitland M.L., Seitzer J., O’Connell D., Walsh K.R., Wood K., et al.  CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N. Engl. J. Med. 2021;385:493–502. doi: 10.1056/NEJMoa2107454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2107454</ArticleId>
            <ArticleId IdType="pubmed">34215024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urits I., Swanson D., Swett M.C., Patel A., Berardino K., Amgalan A., Berger A.A., Kassem H., Kaye A.D., Viswanath O. A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis. Neurol. Ther. 2020;9:301–315. doi: 10.1007/s40120-020-00208-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40120-020-00208-1</ArticleId>
            <ArticleId IdType="pmc">PMC7606409</ArticleId>
            <ArticleId IdType="pubmed">32785879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKinsey &amp; Company  Gene Therapy Coming of Age: Opportunities and Challenges to Getting Ahead. 2019.  [(accessed on 18 July 2021)].  Available online:  https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/gene-therapy-coming-of-age-opportunities-and-challenges-to-getting-ahead.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang W.W., Li L., Li D., Liu J., Li X., Li W., Xu X., Zhang M.J., Chandler L.A., Lin H., et al.  The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. Hum. Gene Ther. 2018;29:160–179. doi: 10.1089/hum.2017.218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2017.218</ArticleId>
            <ArticleId IdType="pubmed">29338444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moran N. First gene therapy approved. Nat. Biotechnol. 2012;30:1153. doi: 10.1038/nbt1212-1153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt1212-1153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration  FDA Approval Brings First Gene Therapy to the United States.  [(accessed on 31 May 2021)];2017  Available online:  https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states.</Citation>
        </Reference>
        <Reference>
          <Citation>Gene Therapy Net  Gene Therapy Products on the Market. 2021.  [(accessed on 14 July 2021)].  Available online:  https://www.genetherapynet.com/gene-therapy-products-on-the-market/624-gene-therapy-products-on-the-market.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Bardhan A., Bruckner-Tuderman L., Chapple I.L.C., Fine J.D., Harper N., Has C., Magin T.M., Marinkovich M.P., Marshall J.F., McGrath J.A., et al.  Epidermolysis bullosa. Nat. Rev. Dis. Primers. 2020;6:78. doi: 10.1038/s41572-020-0210-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-020-0210-0</ArticleId>
            <ArticleId IdType="pubmed">32973163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonafont J., Mencía A., Chacón-Solano E., Srifa W., Vaidyanathan S., Romano R., Garcia M., Hervás-Salcedo R., Ugalde L., Duarte B., et al.  Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing. Mol. Ther. 2021;29:2008–2018. doi: 10.1016/j.ymthe.2021.02.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2021.02.019</ArticleId>
            <ArticleId IdType="pmc">PMC8178438</ArticleId>
            <ArticleId IdType="pubmed">33609734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacków J., Guo Z., Hansen C., Abaci H.E., Doucet Y.S., Shin J.U., Hayashi R., DeLorenzo D., Kabata Y., Shinkuma S., et al.  CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells. Proc. Natl. Acad. Sci. USA. 2019;116:26846–26852. doi: 10.1073/pnas.1907081116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1907081116</ArticleId>
            <ArticleId IdType="pmc">PMC6936361</ArticleId>
            <ArticleId IdType="pubmed">31818947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hainzl S., Peking P., Kocher T., Murauer E.M., Larcher F., Rio M.D., Duarte B., Steiner M., Klausegger A., Bauer J.W., et al.  COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa. Mol. Ther. 2017;25:2573–2584. doi: 10.1016/j.ymthe.2017.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2017.07.005</ArticleId>
            <ArticleId IdType="pmc">PMC5675435</ArticleId>
            <ArticleId IdType="pubmed">28800953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pulkkinen L., Uitto J. Mutation analysis and molecular genetics of epidermolysis bullosa. Matrix Biol. 1999;18:29–42. doi: 10.1016/S0945-053X(98)00005-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0945-053X(98)00005-5</ArticleId>
            <ArticleId IdType="pubmed">10367729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinkovich M.P., Tang J.Y. Gene Therapy for Epidermolysis Bullosa. J. Investig. Dermatol. 2019;139:1221–1226. doi: 10.1016/j.jid.2018.11.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2018.11.036</ArticleId>
            <ArticleId IdType="pubmed">31068252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christiano A.M., Greenspan D.S., Lee S., Uitto J. Cloning of human type VII collagen. Complete primary sequence of the alpha 1(VII) chain and identification of intragenic polymorphisms. J. Biol. Chem. 1994;269:20256–20262. doi: 10.1016/S0021-9258(17)31984-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0021-9258(17)31984-1</ArticleId>
            <ArticleId IdType="pubmed">8051117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodley D.T., Keene D.R., Atha T., Huang Y., Ram R., Kasahara N., Chen M. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol. Ther. 2004;10:318–326. doi: 10.1016/j.ymthe.2004.05.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2004.05.016</ArticleId>
            <ArticleId IdType="pubmed">15294178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerstin B., Kaufmann H.B., Galy A., Schambach A., Grez M. Gene therapy on the move. EMBO Mol. Med. 2013;5:1642–1661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3840483</ArticleId>
            <ArticleId IdType="pubmed">24106209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robbins P.B., Sheu S.M., Goodnough J.B., Khavari P.A. Impact of laminin 5 beta3 gene versus protein replacement on gene expression patterns in junctional epidermolysis bullosa. Hum. Gene Ther. 2001;12:1443–1448. doi: 10.1089/104303401750298599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/104303401750298599</ArticleId>
            <ArticleId IdType="pubmed">11485635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seitz C.S., Giudice G.J., Balding S.D., Marinkovich M.P., Khavari P.A. BP180 gene delivery in junctional epidermolysis bullosa. Gene Ther. 1999;6:42–47. doi: 10.1038/sj.gt.3300809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.gt.3300809</ArticleId>
            <ArticleId IdType="pubmed">10341874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency  EU Clinical Trial Register. 2021.  [(accessed on 11 May 2021)].  Available online:  https://www.clinicaltrialsregister.eu/</Citation>
        </Reference>
        <Reference>
          <Citation>National Institutes of Health—US National Library of Medicine.  [(accessed on 11 June 2021)];2021  Available online:  www.clinicaltrials.gov.</Citation>
        </Reference>
        <Reference>
          <Citation>Hirsch T., Rothoeft T., Teig N., Bauer J.W., Pellegrini G., De Rosa L., Scaglione D., Reichelt J., Klausegger A., Kneisz D., et al.  Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551:327–332. doi: 10.1038/nature24487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature24487</ArticleId>
            <ArticleId IdType="pmc">PMC6283270</ArticleId>
            <ArticleId IdType="pubmed">29144448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Rosa L., Carulli S., Cocchiarella F., Quaglino D., Enzo E., Franchini E., Giannetti A., De Santis G., Recchia A., Pellegrini G., et al.  Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa. Stem Cell Rep. 2014;2:1–8. doi: 10.1016/j.stemcr.2013.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stemcr.2013.11.001</ArticleId>
            <ArticleId IdType="pmc">PMC3916757</ArticleId>
            <ArticleId IdType="pubmed">24511464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Community College Bioscience  Castle Creek Bioscience.  [(accessed on 28 July 2021)].  Available online:  https://castlecreekbio.com/autologous-fibroblast-pipeline/gene-therapy-dystrophic-epidermolysis-bullosa/</Citation>
        </Reference>
        <Reference>
          <Citation>Abeona Therapeutics  Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting. 2021.  [(accessed on 22 August 2021)].  Available online:  https://www.abeonatherapeutics.com/</Citation>
        </Reference>
        <Reference>
          <Citation>Eichstadt S., Barriga M., Ponakala A., Teng C., Nguyen N.T., Siprashvili Z., Nazaroff J., Gorell E.S., Chiou A.S., Taylor L., et al.  Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI Insight. 2019;4 doi: 10.1172/jci.insight.130554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.130554</ArticleId>
            <ArticleId IdType="pmc">PMC6795403</ArticleId>
            <ArticleId IdType="pubmed">31578311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supp D.M., Hahn J.M., Combs K.A., McFarland K.L., Schwentker A., Boissy R.E., Boyce S.T., Powell H.M., Lucky A.W. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes. Cell Transpl. 2019;28:1242–1256. doi: 10.1177/0963689719857657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0963689719857657</ArticleId>
            <ArticleId IdType="pmc">PMC6767893</ArticleId>
            <ArticleId IdType="pubmed">31271052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chavanas S., Bodemer C., Rochat A., Hamel-Teillac D., Ali M., Irvine A.D., Bonafé J.-L., Wilkinson J., Taïeb A., Barrandon Y., et al.  Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 2000;25:141–142. doi: 10.1038/75977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/75977</ArticleId>
            <ArticleId IdType="pubmed">10835624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di W.L., Larcher F., Semenova E., Talbot G.E., Harper J.I., Del Rio M., Thrasher A.J., Qasim W. Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol. Ther. 2011;19:408–416. doi: 10.1038/mt.2010.201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2010.201</ArticleId>
            <ArticleId IdType="pmc">PMC3034839</ArticleId>
            <ArticleId IdType="pubmed">20877344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di W.L., Lwin S.M., Petrova A., Bernadis C., Syed F., Farzaneh F., Moulding D., Martinez A.E., Sebire N.J., Rampling D., et al.  Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial. Hum. Gene Ther. 2019;30:1067–1078. doi: 10.1089/hum.2019.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2019.049</ArticleId>
            <ArticleId IdType="pubmed">31288584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krishnan S., Agarwal P., Freedman J.C., O’Malley M.E., Regula L.K., Krystal Biotech Inc.  Compositions and Methods for the Treatment of Autosomal Recessive Congenital Ichthyosis. 10,525,090. U.S. Patent. 2020 July 1;</Citation>
        </Reference>
        <Reference>
          <Citation>Krystal Biotech  Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa. 2021.  [(accessed on 7 July 2021)].  Available online:  https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-completion-patient-enrollment-gem-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Amryt Pharma  Amryt Pharma Corporate Overview March 2021.  [(accessed on 13 July 2021)].  Available online:  https://www.amrytpharma.com/wp-content/uploads/2021/03/AMRYT-Corporate-Overview-Presentation-March-2021-FINAL.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Intrado  Amryt Receives Positive Opinion From EMA on Orphan Drug Designation for AP103. 2020.  [(accessed on 26 June 2021)].  Available online:  https://www.globenewswire.com/fr/news-release/2020/09/15/2093560/0/en/AMRYT-RECEIVES-POSITIVE-OPINION-FROM-EMA-ON-ORPHAN-DRUG-DESIGNATION-FOR-AP103.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Jackow J., Guo Z., Abaci E., Doucet Y., Hansen C., Salas-Alanis J., Christiano A. Biallelic correction of recessive dystrophic epidermolysis bullosa mutations in iPSCs using CRISPR/Cas9- based genome editing. J. Investig. Dermatol. 2017;137:S225. doi: 10.1016/j.jid.2017.07.187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2017.07.187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webber B.R., Osborn M.J., McElroy A.N., Twaroski K., Lonetree C.-l., DeFeo A.P., Xia L., Eide C., Lees C.J., McElmurry R.T., et al.  CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. NPJ Regen. Med. 2016;1:16014. doi: 10.1038/npjregenmed.2016.14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npjregenmed.2016.14</ArticleId>
            <ArticleId IdType="pmc">PMC5328670</ArticleId>
            <ArticleId IdType="pubmed">28250968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonafont J., Mencía Á., García M., Torres R., Rodríguez S., Carretero M., Chacón-Solano E., Modamio-Høybjør S., Marinas L., León C., et al.  Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing. Mol. Ther. 2019;27:986–998. doi: 10.1016/j.ymthe.2019.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2019.03.007</ArticleId>
            <ArticleId IdType="pmc">PMC6520462</ArticleId>
            <ArticleId IdType="pubmed">30930113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan T., Pan Q., Ping Y. Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders. Sci. Adv. 2021;7:eabe2888. doi: 10.1126/sciadv.abe2888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.abe2888</ArticleId>
            <ArticleId IdType="pmc">PMC7946375</ArticleId>
            <ArticleId IdType="pubmed">33692106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koller U., Bauer J.W. Gene Replacement Therapies for Genodermatoses: A Status Quo. Front. Genet. 2021;12:658295. doi: 10.3389/fgene.2021.658295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fgene.2021.658295</ArticleId>
            <ArticleId IdType="pmc">PMC8120236</ArticleId>
            <ArticleId IdType="pubmed">33995490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker C., Hayden M.S. Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease. F1000Research. 2020;9:281. doi: 10.12688/f1000research.23185.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12688/f1000research.23185.1</ArticleId>
            <ArticleId IdType="pmc">PMC7265575</ArticleId>
            <ArticleId IdType="pubmed">32528662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rashidghamat E., Kadiyirire T., Ayis S., Petrof G., Liu L., Pullabhatla V., Ainali C., Guy A., Aristodemou S., McMillan J.R., et al.  Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. J. Am. Acad. Dermatol. 2020;83:447–454. doi: 10.1016/j.jaad.2019.11.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2019.11.038</ArticleId>
            <ArticleId IdType="pubmed">31786163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrof G., Lwin S.M., Martinez-Queipo M., Abdul-Wahab A., Tso S., Mellerio J.E., Slaper-Cortenbach I., Boelens J.J., Tolar J., Veys P., et al.  Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa. J. Investig. Dermatol. 2015;135:2319–2321. doi: 10.1038/jid.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5696540</ArticleId>
            <ArticleId IdType="pubmed">25905587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Darouti M., Fawzy M., Amin I., Abdel Hay R., Hegazy R., Gabr H., El Maadawi Z. Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: A randomized controlled trial. Dermatol. Ther. 2016;29:96–100. doi: 10.1111/dth.12305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dth.12305</ArticleId>
            <ArticleId IdType="pubmed">26439431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov  A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa.  [(accessed on 18 June 2021)];2020  Available online:  https://clinicaltrials.gov/ct2/show/NCT04599881.</Citation>
        </Reference>
        <Reference>
          <Citation>Sarkar T., Sarkar S., Gangopadhyay D.N. Gene Therapy and its Application in Dermatology. Indian J. Dermatol. 2020;65:341–350. doi: 10.4103/ijd.IJD_323_20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/ijd.IJD_323_20</ArticleId>
            <ArticleId IdType="pmc">PMC7640808</ArticleId>
            <ArticleId IdType="pubmed">33165431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prodinger C.M., Reichelt J., Bauer J.W., Laimer M. Current and Future Perspectives of Stem Cell Therapy in Dermatology. Ann. Dermatol. 2017;29:667–687. doi: 10.5021/ad.2017.29.6.667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5021/ad.2017.29.6.667</ArticleId>
            <ArticleId IdType="pmc">PMC5705348</ArticleId>
            <ArticleId IdType="pubmed">29200755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Busch K.H., Bender R., Walezko N., Aziz H., Altintas M.A., Aust M.C. Combination of medical needling and non-cultured autologous skin cell transplantation (ReNovaCell) for repigmentation of hypopigmented burn scars. Burns. 2016;42:1556–1566. doi: 10.1016/j.burns.2016.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.burns.2016.04.009</ArticleId>
            <ArticleId IdType="pubmed">27156803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper-Jones B., Visintini S.  CADTH Issues in Emerging Health Technologies. Canadian Agency for Drugs and Technologies in Health; Ottawa, ON, Canada: 2016. A Noncultured Autologous Skin Cell Spray Graft for the Treatment of Burns; pp. 1–11.</Citation>
        </Reference>
        <Reference>
          <Citation>Shin T.H., Kim H.S., Choi S.W., Kang K.S. Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action. Int. J. Mol. Sci. 2017;18:244.  doi: 10.3390/ijms18020244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18020244</ArticleId>
            <ArticleId IdType="pmc">PMC5343781</ArticleId>
            <ArticleId IdType="pubmed">28125063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orr R.M. Technology evaluation: Fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Curr. Opin. Mol. Ther. 2001;3:288–294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11497353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoy S.M. Patisiran: First Global Approval. Drugs. 2018;78:1625–1631. doi: 10.1007/s40265-018-0983-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-018-0983-6</ArticleId>
            <ArticleId IdType="pubmed">30251172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akinc A., Maier M.A., Manoharan M., Fitzgerald K., Jayaraman M., Barros S., Ansell S., Du X., Hope M.J., Madden T.D., et al.  The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 2019;14:1084–1087. doi: 10.1038/s41565-019-0591-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41565-019-0591-y</ArticleId>
            <ArticleId IdType="pubmed">31802031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong H., Veedu R.N., Diermeier S.D. Recent advances in oligonucleotide therapeutics in oncology. Int. J. Mol. Sci. 2021;22:3295.  doi: 10.3390/ijms22073295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22073295</ArticleId>
            <ArticleId IdType="pmc">PMC8036554</ArticleId>
            <ArticleId IdType="pubmed">33804856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leachman S.A., Hickerson R.P., Schwartz M.E., Bullough E.E., Hutcherson S.L., Boucher K.M., Hansen C.D., Eliason M.J., Srivatsa G.S., Kornbrust D.J., et al.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. 2010;18:442–446. doi: 10.1038/mt.2009.273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2009.273</ArticleId>
            <ArticleId IdType="pmc">PMC2839285</ArticleId>
            <ArticleId IdType="pubmed">19935778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang S., Kim J., Ahn M., Kim J., Heo M.G., Min D.H., Won C. RNAi nanotherapy for fibrosis: Highly durable knockdown of CTGF/CCN-2 using siRNA-DegradaBALL (LEM-S401) to treat skin fibrotic diseases. Nanoscale. 2020;12:6385–6393. doi: 10.1039/C9NR10305H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C9NR10305H</ArticleId>
            <ArticleId IdType="pubmed">32134425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gale J.D., Jensen J., Berman G., Freimuth W., Li G., Pleil A., Kutty M., Rosenthal A., Boswell C.B., Noah V., et al.  A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring. Plast. Reconstr. Surg. Glob. Open. 2018;6:e1861. doi: 10.1097/GOX.0000000000001861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/GOX.0000000000001861</ArticleId>
            <ArticleId IdType="pmc">PMC6191237</ArticleId>
            <ArticleId IdType="pubmed">30349773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han-soo L. Hugel Completes P1 Clinical Trial on Hypertrophic Scar Treatment. 2018.  [(accessed on 25 June 2021)].  Available online:  http://www.koreabiomed.com/news/articleView.html?idxno=3298.</Citation>
        </Reference>
        <Reference>
          <Citation>Sirnaomics  Science. 2021.  [(accessed on 15 May 2021)].  Available online:  https://sirnaomics.com/science/</Citation>
        </Reference>
        <Reference>
          <Citation>Zuidam J.V. Delving into RXi’s RNAi Delivery Platform. 2017.  [(accessed on 15 May 2021)].  Available online:  https://www.drugdiscoverytrends.com/delving-into-rxis-rnai-delivery-platform/#.Wg3exJa_LPE.twitter.</Citation>
        </Reference>
        <Reference>
          <Citation>National Institutes of Health—US National Library of Medicine  A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars.  [(accessed on 15 May 2021)];2021  Available online:  https://clinicaltrials.gov/ct2/show/NCT02246465.</Citation>
        </Reference>
        <Reference>
          <Citation>Bae C.J., Lee J.W., Shim S.B., Jee S.W., Lee S.H., Woo J.M., Lee C.K., Hwang D.Y. GATA binding protein 3 overexpression and suppression significantly contribute to the regulation of allergic skin inflammation. Int. J. Mol. Med. 2011;28:171–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21537830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeitvogel J., Jokmin N., Rieker S., Klug I., Brandenberger C., Werfel T. GATA3 regulates FLG and FLG2 expression in human primary keratinocytes. Sci. Rep. 2017;7:1–11. doi: 10.1038/s41598-017-10252-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-10252-x</ArticleId>
            <ArticleId IdType="pmc">PMC5605628</ArticleId>
            <ArticleId IdType="pubmed">28928464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sterna Biologicals  Pipeline Sterna Biologicals. 2021.  [(accessed on 26 July 2021)].  Available online:  https://www.sterna-biologicals.com/pipeline.</Citation>
        </Reference>
        <Reference>
          <Citation>Bremer J., Bornert O., Nyström A., Gostynski A., Jonkman M.F., Aartsma-Rus A., van den Akker P.C., Pasmooij A.M. Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa. Mol. Ther. Nucleic Acids. 2016;5:e379. doi: 10.1038/mtna.2016.87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mtna.2016.87</ArticleId>
            <ArticleId IdType="pubmed">27754488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bornert O., Kühl T., Bremer J., Van Den Akker P.C., Pasmooij A.M.G., Nyström A. Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy. Mol. Ther. 2016;24:1302–1311. doi: 10.1038/mt.2016.92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2016.92</ArticleId>
            <ArticleId IdType="pmc">PMC5088769</ArticleId>
            <ArticleId IdType="pubmed">27157667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turczynski S., Titeux M., Tonasso L., Décha A., Ishida-Yamamoto A., Hovnanian A. Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model. J. Investig. Dermatol. 2016;136:2387–2395. doi: 10.1016/j.jid.2016.07.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2016.07.029</ArticleId>
            <ArticleId IdType="pubmed">27498345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bornert O., Hogervorst M., Nauroy P., Bischof J., Swildens J., Athanasiou I., Tufa S.F., Keene D.R., Kiritsi D., Hainzl S., et al.  QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study. J. Investig. Dermatol. 2021;141:883–893.e6. doi: 10.1016/j.jid.2020.08.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2020.08.018</ArticleId>
            <ArticleId IdType="pubmed">32946877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.T., Lee K.-M., Park H.-J., Jin S.-E., Ahn W.S., Kim C.-K. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J. Gene Med. 2009;11:26–37. doi: 10.1002/jgm.1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jgm.1268</ArticleId>
            <ArticleId IdType="pubmed">19006098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Exicure Inc.   Annual Report on Form K-10. United States Securities and Exchange Commission; Washington, DC, USA: 2019.  [(accessed on 2 August 2021)].  Available online:  www.annualreports.com.</Citation>
        </Reference>
        <Reference>
          <Citation>Kapadia C.H., Melamed J.R., Day E.S. Spherical Nucleic Acid Nanoparticles: Therapeutic Potential. BioDrugs. 2018;32:297–309. doi: 10.1007/s40259-018-0290-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40259-018-0290-5</ArticleId>
            <ArticleId IdType="pmc">PMC6428072</ArticleId>
            <ArticleId IdType="pubmed">29959665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allergan Pays Exicure $25M to Discover Nucleic Acid Hair Loss Drugs. 2019.  [(accessed on 12 August 2021)].  Available online:  https://www.fiercebiotech.com/biotech/allergan-pays-exicure-25m-to-discover-nucleic-acid-hair-loss-drugs.</Citation>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov  Oblimersen and Dacarbazine in Treating Patients with Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301.  [(accessed on 2 August 2021)];2003  Available online:  https://clinicaltrials.gov/ct2/show/NCT00070343.</Citation>
        </Reference>
        <Reference>
          <Citation>Hong C.A., Nam Y.S. Functional nanostructures for effective delivery of small interfering RNA therapeutics. Theranostics. 2014;4:1211–1232. doi: 10.7150/thno.8491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.8491</ArticleId>
            <ArticleId IdType="pmc">PMC4183999</ArticleId>
            <ArticleId IdType="pubmed">25285170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D., Tai P.W.L., Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 2019;18:358–378. doi: 10.1038/s41573-019-0012-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41573-019-0012-9</ArticleId>
            <ArticleId IdType="pmc">PMC6927556</ArticleId>
            <ArticleId IdType="pubmed">30710128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung Y.K., Kim S.W. Recent advances in the development of gene delivery systems. Biomater. Res. 2019;23:8. doi: 10.1186/s40824-019-0156-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40824-019-0156-z</ArticleId>
            <ArticleId IdType="pmc">PMC6417261</ArticleId>
            <ArticleId IdType="pubmed">30915230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lundstrom K. Viral Vectors in Gene Therapy. Diseases. 2018;6:42.  doi: 10.3390/diseases6020042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/diseases6020042</ArticleId>
            <ArticleId IdType="pmc">PMC6023384</ArticleId>
            <ArticleId IdType="pubmed">29883422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chamorro C., Mencía A., Almarza D., Duarte B., Büning H., Sallach J., Hausser I., Del Río M., Larcher F., Murillas R. Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes. Mol. Ther. Nucleic Acids. 2016;5:e307. doi: 10.1038/mtna.2016.19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mtna.2016.19</ArticleId>
            <ArticleId IdType="pmc">PMC5014520</ArticleId>
            <ArticleId IdType="pubmed">27045209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colella P., Ronzitti G., Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol. Ther. Methods Clin. Dev. 2018;8:87–104. doi: 10.1016/j.omtm.2017.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omtm.2017.11.007</ArticleId>
            <ArticleId IdType="pmc">PMC5758940</ArticleId>
            <ArticleId IdType="pubmed">29326962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verdera H.C., Kuranda K., Mingozzi F. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. Mol. Ther. 2020;28:723–746. doi: 10.1016/j.ymthe.2019.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2019.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC7054726</ArticleId>
            <ArticleId IdType="pubmed">31972133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal A., Kumbhojkar N., Reilly C., Dharamdasani V., Ukidve A., Ingber D.E., Mitragotri S. Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations. Sci. Adv. 2020;6 doi: 10.1126/sciadv.abb6049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.abb6049</ArticleId>
            <ArticleId IdType="pmc">PMC7439648</ArticleId>
            <ArticleId IdType="pubmed">32832675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ball R.L., Bajaj P., Whitehead K.A. Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract. Sci. Rep. 2018;8:1–12. doi: 10.1038/s41598-018-20632-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-20632-6</ArticleId>
            <ArticleId IdType="pmc">PMC5794865</ArticleId>
            <ArticleId IdType="pubmed">29391566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin P.Y., Chiu Y.L., Huang J.H., Chuang E.Y., Mi F.L., Lin K.J., Juang J.H., Sung H.W., Leong K.W. Oral Nonviral Gene Delivery for Chronic Protein Replacement Therapy. Adv. Sci. 2018;5:1701079. doi: 10.1002/advs.201701079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/advs.201701079</ArticleId>
            <ArticleId IdType="pmc">PMC6096992</ArticleId>
            <ArticleId IdType="pubmed">30128227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forbes D.C., Peppas N.A. Oral delivery of small RNA and DNA. J. Control. Release. 2012;162:438–445. doi: 10.1016/j.jconrel.2012.06.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2012.06.037</ArticleId>
            <ArticleId IdType="pubmed">22771979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>enGene  . Pioneering Oral Delivery for Gene Therapy. Nature Research Custom Media; London, UK: 2021. </Citation>
        </Reference>
        <Reference>
          <Citation>Gennemark P., Walter K., Clemmensen N., Rekić D., Nilsson C.A.M., Knöchel J., Hölttä M., Wernevik L., Rosengren B., Kakol-Palm D., et al.  An oral antisense oligonucleotide for PCSK9 inhibition. Sci. Transl. Med. 2021;13:eabe9117. doi: 10.1126/scitranslmed.abe9117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abe9117</ArticleId>
            <ArticleId IdType="pubmed">33980578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhavsar M.D., Amiji M.M. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS) J. Control. Release. 2007;119:339–348. doi: 10.1016/j.jconrel.2007.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2007.03.006</ArticleId>
            <ArticleId IdType="pubmed">17475358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zakrewsky M., Kumar S., Mitragotri S. Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges. J. Control. Release. 2015;219:445–456. doi: 10.1016/j.jconrel.2015.09.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2015.09.017</ArticleId>
            <ArticleId IdType="pmc">PMC5192040</ArticleId>
            <ArticleId IdType="pubmed">26385169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dokka S., Cooper S.R., Kelly S., Hardee G.E., Karras J.G. Dermal delivery of topically applied oligonucleotides via follicular transport in mouse skin. J. Investig. Dermatol. 2005;124:971–975. doi: 10.1111/j.0022-202X.2005.23672.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.0022-202X.2005.23672.x</ArticleId>
            <ArticleId IdType="pubmed">15854038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng D., Giljohann D.A., Chen D.L., Massich M.D., Wang X.-Q., Iordanov H., Mirkin C.A., Paller A.S. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc. Natl. Acad. Sci. USA. 2012;109:11975–11980. doi: 10.1073/pnas.1118425109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1118425109</ArticleId>
            <ArticleId IdType="pmc">PMC3409786</ArticleId>
            <ArticleId IdType="pubmed">22773805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang D., Zhao D., Wang X., Li C., Yang T., Du L., Wei Z., Cheng Q., Cao H., Liang Z., et al.  Efficient delivery of nucleic acid molecules into skin by combined use of microneedle roller and flexible interdigitated electroporation array. Theranostics. 2018;8:2361–2376. doi: 10.7150/thno.23438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.23438</ArticleId>
            <ArticleId IdType="pmc">PMC5928895</ArticleId>
            <ArticleId IdType="pubmed">29721085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dul M., Stefanidou M., Porta P., Serve J., O’Mahony C., Malissen B., Henri S., Levin Y., Kochba E., Wong F.S., et al.  Hydrodynamic gene delivery in human skin using a hollow microneedle device. J. Control. Release. 2017;265:120–131. doi: 10.1016/j.jconrel.2017.02.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2017.02.028</ArticleId>
            <ArticleId IdType="pubmed">28254630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brownstone N.D., Hong J., Mosca M., Hadeler E., Liao W., Bhutani T., Koo J. Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics. 2021;15:39–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7896737</ArticleId>
            <ArticleId IdType="pubmed">33623366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison G.A. Insulin in alcoholic solution by the mouth. Br. Med. J. 1923;2:1204–1205. doi: 10.1136/bmj.2.3286.1204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.2.3286.1204</ArticleId>
            <ArticleId IdType="pmc">PMC2317756</ArticleId>
            <ArticleId IdType="pubmed">20771392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>New R. Oral Delivery of Biologics via the Intestine. Pharmaceutics. 2020;13:18.  doi: 10.3390/pharmaceutics13010018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics13010018</ArticleId>
            <ArticleId IdType="pmc">PMC7824380</ArticleId>
            <ArticleId IdType="pubmed">33374222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuvia S., Atsmon J., Teichman S.L., Katz S., Salama P., Pelled D., Landau I., Karmeli I., Bidlingmaier M., Strasburger C.J., et al.  Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression. J. Clin. Endocrinol. Metab. 2012;97:2362–2369. doi: 10.1210/jc.2012-1179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-1179</ArticleId>
            <ArticleId IdType="pubmed">22539587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Overgaard R.V., Navarria A., Ingwersen S.H., Bækdal T.A., Kildemoes R.J. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin. Pharmacokinet. 2021;60:1335–1348. doi: 10.1007/s40262-021-01025-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40262-021-01025-x</ArticleId>
            <ArticleId IdType="pmc">PMC8505367</ArticleId>
            <ArticleId IdType="pubmed">33969456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley S.T., Bækdal T.A., Vegge A., Maarbjerg S.J., Pyke C., Ahnfelt-Rønne J., Madsen K.G., Schéele S.G., Alanentalo T., Kirk R.K., et al.  Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci. Transl. Med. 2018;10:eaar7047. doi: 10.1126/scitranslmed.aar7047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aar7047</ArticleId>
            <ArticleId IdType="pubmed">30429357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher S., Brayden D.J., Casettari L., Illum L. Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update. Pharmaceutics. 2019;11:41.  doi: 10.3390/pharmaceutics11010041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics11010041</ArticleId>
            <ArticleId IdType="pmc">PMC6359609</ArticleId>
            <ArticleId IdType="pubmed">30669434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Twarog C., Fattah S., Heade J., Maher S., Fattal E., Brayden D.J. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C(10)) Pharmaceutics. 2019;11:78.  doi: 10.3390/pharmaceutics11020078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics11020078</ArticleId>
            <ArticleId IdType="pmc">PMC6410172</ArticleId>
            <ArticleId IdType="pubmed">30781867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuvia S., Pelled D., Marom K., Salama P., Levin-Arama M., Karmeli I., Idelson G.H., Landau I., Mamluk R. A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms. Pharm. Res. 2014;31:2010–2021. doi: 10.1007/s11095-014-1303-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-014-1303-9</ArticleId>
            <ArticleId IdType="pmc">PMC4153969</ArticleId>
            <ArticleId IdType="pubmed">24558008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salama P., Mamluk R., Marom K., Weinstein I., Tzabari M. Chiasma, Inc. Pharmaceutical Compositions and Related Methods of Delivery. 8,535,695. U.S. Patent. 2013 September 17;</Citation>
        </Reference>
        <Reference>
          <Citation>Maher S., Leonard T.W., Jacobsen J., Brayden D.J. Safety and efficacy of sodium caprate in promoting oral drug absorption: From in vitro to the clinic. Adv. Drug Deliv. Rev. 2009;61:1427–1449. doi: 10.1016/j.addr.2009.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2009.09.006</ArticleId>
            <ArticleId IdType="pubmed">19800376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonard T.W., Lynch J., McKenna M.J., Brayden D.J. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert. Opin. Drug Deliv. 2006;3:685–692. doi: 10.1517/17425247.3.5.685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/17425247.3.5.685</ArticleId>
            <ArticleId IdType="pubmed">16948563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halberg I.B., Lyby K., Wassermann K., Heise T., Plum-Mörschel L., Zijlstra E. The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects. Clin. Pharm. 2019;58:1497–1504. doi: 10.1007/s40262-019-00772-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40262-019-00772-2</ArticleId>
            <ArticleId IdType="pmc">PMC6856260</ArticleId>
            <ArticleId IdType="pubmed">31093929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brayden D.J., Hill T.A., Fairlie D.P., Maher S., Mrsny R.J. Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. Adv. Drug Deliv. Rev. 2020;157:2–36. doi: 10.1016/j.addr.2020.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2020.05.007</ArticleId>
            <ArticleId IdType="pubmed">32479930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee A., Ibsen K., Brown T., Chen R., Agatemor C., Mitragotri S. Ionic liquids for oral insulin delivery. Proc. Natl. Acad. Sci. USA. 2018;115:7296–7301. doi: 10.1073/pnas.1722338115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1722338115</ArticleId>
            <ArticleId IdType="pmc">PMC6048483</ArticleId>
            <ArticleId IdType="pubmed">29941553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitragotri S., Banerjee A., Brown T., Ibsen K., Agatemor C. Ionic Liquids For Internal Delivery. 16,762,361. U.S. Patent. 2018 November 16;</Citation>
        </Reference>
        <Reference>
          <Citation>Tillman L.G., Geary R.S., Hardee G.E. Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 2008;97:225–236. doi: 10.1002/jps.21084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.21084</ArticleId>
            <ArticleId IdType="pubmed">17721945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ionis  Ionis Highlights Achievements, Commercial Strategy and Technology Advancements at Investor Day. 2020.  [(accessed on 7 July 2021)].  Available online:  www.ionispharma.com.</Citation>
        </Reference>
        <Reference>
          <Citation>Taylor N.P. Ionis Taps Progenity to Create Oral Antisense Therapies. 2021.  [(accessed on 7 July 2021)].  Available online:  https://www.fiercepharma.com/drug-delivery/ionis-taps-progenity-to-create-oral-antisense-therapies.</Citation>
        </Reference>
        <Reference>
          <Citation>Hyun E.J., Hasan M.N., Kang S.H., Cho S., Lee Y.K. Oral siRNA delivery using dual transporting systems to efficiently treat colorectal liver metastasis. Int. J. Pharm. 2019;555:250–258. doi: 10.1016/j.ijpharm.2018.11.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2018.11.009</ArticleId>
            <ArticleId IdType="pubmed">30399434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Driscoll C.M., Bernkop-Schnürch A., Friedl J.D., Préat V., Jannin V. Oral delivery of non-viral nucleic acid-based therapeutics—Do we have the guts for this? Eur. J. Pharm. Sci. 2019;133:190–204. doi: 10.1016/j.ejps.2019.03.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejps.2019.03.027</ArticleId>
            <ArticleId IdType="pubmed">30946964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alnylam Pharmaceuticals  Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery. 2019.  [(accessed on 16 May 2021)].  Available online:  https://www.biospace.com/article/releases/alnylam-announces-progress-with-rnai-therapeutics-platform-including-oral-route-of-administration-and-cns-and-ocular-delivery-/</Citation>
        </Reference>
        <Reference>
          <Citation>DNAlite  Gatrointestinal Gene Therapy Create Better Biological Medicines. 2021.  [(accessed on 27 July 2021)].  Available online:  https://www.dnalite.com/</Citation>
        </Reference>
        <Reference>
          <Citation>Granhall C., Donsmark M., Blicher T.M., Golor G., Søndergaard F.L., Thomsen M., Bækdal T.A. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. Clin. Pharmacokinet. 2019;58:781–791. doi: 10.1007/s40262-018-0728-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40262-018-0728-4</ArticleId>
            <ArticleId IdType="pubmed">30565096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellriegel E.T., Bjornsson T.D., Hauck W.W. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 1996;60:601–607. doi: 10.1016/S0009-9236(96)90208-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0009-9236(96)90208-8</ArticleId>
            <ArticleId IdType="pubmed">8988062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halberg I.B., Lyby K., Wassermann K., Heise T., Zijlstra E., Plum-Morschel L. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: A randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7:179–188. doi: 10.1016/S2213-8587(18)30372-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-8587(18)30372-3</ArticleId>
            <ArticleId IdType="pubmed">30679095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moroz E., Matoori S., Leroux J.C. Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts. Adv. Drug Deliv. Rev. 2016;101:108–121. doi: 10.1016/j.addr.2016.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2016.01.010</ArticleId>
            <ArticleId IdType="pubmed">26826437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caffarel-Salvador E., Abramson A., Langer R., Traverso G. Oral delivery of biologics using drug-device combinations. Curr. Opin. Pharm. 2017;36:8–13. doi: 10.1016/j.coph.2017.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coph.2017.07.003</ArticleId>
            <ArticleId IdType="pmc">PMC5732838</ArticleId>
            <ArticleId IdType="pubmed">28779684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imran M., Rani Therapeutics LLC.  Therapeutic Agent Preparations Comprising Liraglutide for Delivery into a Lumen of the Intestinal Tract Using a Swallowable Drug Delivery Device. 8,809,271. U.S. Patent. 2014 August 19;</Citation>
        </Reference>
        <Reference>
          <Citation>Dhalla A.K., Al-Shamsie Z., Beraki S., Dasari A., Fung L.C., Fusaro L., Garapaty A., Gutierrez B., Gratta D., Hashim M., et al.  A robotic pill for oral delivery of biotherapeutics: Safety, tolerability, and performance in healthy subjects. Drug Deliv. Transl. Res. 2021:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33604838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abramson A., Caffarel-Salvador E., Khang M., Dellal D., Silverstein D., Gao Y., Frederiksen M.R., Vegge A., Hubálek F., Water J.J., et al.  An ingestible self-orienting system for oral delivery of macromolecules. Science. 2019;363:611–615. doi: 10.1126/science.aau2277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aau2277</ArticleId>
            <ArticleId IdType="pmc">PMC6430586</ArticleId>
            <ArticleId IdType="pubmed">30733413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abramson A., Caffarel-Salvador E., Soares V., Minahan D., Tian R.Y., Lu X., Dellal D., Gao Y., Kim S., Wainer J., et al.  A luminal unfolding microneedle injector for oral delivery of macromolecules. Nat. Med. 2019;25:1512–1518. doi: 10.1038/s41591-019-0598-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0598-9</ArticleId>
            <ArticleId IdType="pmc">PMC7218658</ArticleId>
            <ArticleId IdType="pubmed">31591601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babaee S., Pajovic S., Kirtane A.R., Shi J., Caffarel-Salvador E., Hess K., Collins J.E., Tamang S., Wahane A.V., Hayward A.M., et al.  Temperature-responsive biometamaterials for gastrointestinal applications. Sci. Transl. Med. 2019;11:eaau8581. doi: 10.1126/scitranslmed.aau8581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aau8581</ArticleId>
            <ArticleId IdType="pmc">PMC7797624</ArticleId>
            <ArticleId IdType="pubmed">30996082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biograil.  [(accessed on 16 August 2021)].  Available online:  https://biograil.com/</Citation>
        </Reference>
        <Reference>
          <Citation>Progenity™  Oral Biotherapeutics Drug-Device Combinations Using Progenity’s Novel Drug Delivery System (in Development) 2021.  [(accessed on 28 July 2021)].  Available online:  https://www.progenity.com/innovation/oral-biotherapeutics.</Citation>
        </Reference>
        <Reference>
          <Citation>Baywind Bioventures  Propel Biologics™ JetCAP™. 2021.  [(accessed on 28 July 2021)].  Available online:  http://baywindbio.com/jetcap/</Citation>
        </Reference>
        <Reference>
          <Citation>Rhodes C., Casillas J., Baywind Bioventures  Capsule Device for Delivery of Active Agent to Gastrointestinal Tract. 62/722,083. U.S. Patent. 2018 August 23;</Citation>
        </Reference>
        <Reference>
          <Citation>Aran K., Chooljian M., Paredes J., Rafi M., Lee K., Kim A.Y., An J., Yau J.F., Chum H., Conboy I., et al.  An oral microjet vaccination system elicits antibody production in rabbits. Sci. Transl. Med. 2017;9:eaaf6413. doi: 10.1126/scitranslmed.aaf6413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaf6413</ArticleId>
            <ArticleId IdType="pubmed">28275153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Artmonov V., Yanovitska J., Hashimshony D., Cohen J. The development of intestinal mucoadhesive layers for a novel device for oral delivery of macromolecules through the intestinal wall. Pharmaceutics. 2021;13 under review.</Citation>
        </Reference>
        <Reference>
          <Citation>Abramson A., Frederiksen M.R., Vegge A., Jensen B., Poulsen M., Mouridsen B., Jespersen M.O., Kirk R.K., Windum J., Hubalek F., et al.  Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors. Nat. Biotechnol. 2021:1–7. doi: 10.1038/s41587-021-01024-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41587-021-01024-0</ArticleId>
            <ArticleId IdType="pubmed">34462588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pillai O., Kumar N., Dey C.S., Borkute S., Nagalingam S., Panchagnula R. Transdermal iontophoresis of insulin. Part 1: A study on the issues associated with the use of platinum electrodes on rat skin. J Pharm. Pharmacol. 2003;55:1505–1513. doi: 10.1211/0022357022197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1211/0022357022197</ArticleId>
            <ArticleId IdType="pubmed">14713361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>France M.M., Del Rio T., Travers H., Raftery E., Xu K., Langer R., Traverso G., Lennerz J.K., Schoellhammer C.M. Ultra-rapid drug delivery in the oral cavity using ultrasound. J. Control. Release. 2019;304:1–6. doi: 10.1016/j.jconrel.2019.04.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2019.04.037</ArticleId>
            <ArticleId IdType="pubmed">31039376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caffarel-Salvador E., Kim S., Soares V., Tian R.Y., Stern S.R., Minahan D., Yona R., Lu X., Zakaria F.R., Collins J., et al.  A microneedle platform for buccal macromolecule delivery. Sci. Adv. 2021;7:eabe2620. doi: 10.1126/sciadv.abe2620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.abe2620</ArticleId>
            <ArticleId IdType="pubmed">33523951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee A., Wong J., Gogoi R., Brown T., Mitragotri S. Intestinal micropatches for oral insulin delivery. J. Drug Target. 2017;25:608–615. doi: 10.1080/1061186X.2017.1300664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1061186X.2017.1300664</ArticleId>
            <ArticleId IdType="pubmed">28266884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee A., Chen R., Arafin S., Mitragotri S. Intestinal iontophoresis from mucoadhesive patches: A strategy for oral delivery. J. Control. Release. 2019;297:71–78. doi: 10.1016/j.jconrel.2019.01.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2019.01.037</ArticleId>
            <ArticleId IdType="pubmed">30707901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nemeth C.L., Lykins W.R., Tran H., ElSayed M.E.H., Desai T.A. Bottom-Up Fabrication of Multilayer Enteric Devices for the Oral Delivery of Peptides. Pharm. Res. 2019;36:89. doi: 10.1007/s11095-019-2618-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-019-2618-3</ArticleId>
            <ArticleId IdType="pubmed">31004235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fox C.B., Cao Y., Nemeth C.L., Chirra H.D., Chevalier R.W., Xu A.M., Melosh N.A., Desai T.A. Fabrication of Sealed Nanostraw Microdevices for Oral Drug Delivery. ACS Nano. 2016;10:5873–5881. doi: 10.1021/acsnano.6b00809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.6b00809</ArticleId>
            <ArticleId IdType="pmc">PMC5435488</ArticleId>
            <ArticleId IdType="pubmed">27268699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jørgensen J.R., Jepsen M.L., Nielsen L.H., Dufva M., Nielsen H.M., Rades T., Boisen A., Müllertz A. Microcontainers for oral insulin delivery—In vitro studies of permeation enhancement. Eur. J. Pharm. Biopharm. 2019;143:98–105. doi: 10.1016/j.ejpb.2019.08.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpb.2019.08.011</ArticleId>
            <ArticleId IdType="pubmed">31425857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong Y.L., Zou X., McCandler C.A., Kirtane A.R., Ning S., Zhou J., Abid A., Jafari M., Rogner J., Minahan D., et al.  3D-Printed Gastric Resident Electronics. Adv. Mater. Technol. 2019;4:1800490. doi: 10.1002/admt.201800490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/admt.201800490</ArticleId>
            <ArticleId IdType="pmc">PMC6988123</ArticleId>
            <ArticleId IdType="pubmed">32010758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Schaar P.J., Dijksman J.F., Broekhuizen-de Gast H., Shimizu J., van Lelyveld N., Zou H., Iordanov V., Wanke C., Siersema P.D. A novel ingestible electronic drug delivery and monitoring device. Gastrointest. Endosc. 2013;78:520–528. doi: 10.1016/j.gie.2013.03.170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gie.2013.03.170</ArticleId>
            <ArticleId IdType="pubmed">23684148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker D., Zhang J., Heimbach T., Penland R.C., Wanke C., Shimizu J., Kulmatycki K. Novel orally swallowable IntelliCap® device to quantify regional drug absorption in human GI tract using diltiazem as model drug. AAPS PharmSciTech. 2014;15:1490–1497. doi: 10.1208/s12249-014-0172-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12249-014-0172-1</ArticleId>
            <ArticleId IdType="pmc">PMC4245429</ArticleId>
            <ArticleId IdType="pubmed">25023947</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
